Home > Boards > US Listed > Biotechs > Collegium Pharmaceutical (COLL)

Depomed farms out Nucynta sales, will lay off

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Apophis Member Profile
 
Followed By 19
Posts 8,619
Boards Moderated 0
Alias Born 07/11/06
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/19/2019 6:06:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 4:19:26 PM
Collegium to Present at Upcoming Investor Conferences GlobeNewswire Inc. - 5/29/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/17/2019 4:06:14 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/8/2019 4:06:22 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2019 4:03:58 PM
Collegium Reports First Quarter 2019 Financial Results GlobeNewswire Inc. - 5/8/2019 4:01:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/30/2019 4:03:16 PM
Collegium to Participate in Upcoming Investor Conferences GlobeNewswire Inc. - 4/30/2019 4:01:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/30/2019 8:53:45 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/29/2019 6:57:40 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/29/2019 6:54:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/29/2019 6:52:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/29/2019 6:50:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/29/2019 6:46:54 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/29/2019 6:44:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/29/2019 6:41:31 PM
Collegium to Host Conference Call to Discuss First Quarter 2019 Financial Results and Provide Corporate Update GlobeNewswire Inc. - 4/24/2019 4:01:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/17/2019 4:25:31 PM
Market Trends Toward New Normal in Pareteum, Discovery Communications, Midstates Petroleum, Watsco, Collegium Pharmaceutical,... GlobeNewswire Inc. - 4/8/2019 9:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/2/2019 4:22:18 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/2/2019 4:17:15 PM
Collegium Appoints Richard Malamut, M.D., as Chief Medical Officer GlobeNewswire Inc. - 4/2/2019 8:00:00 AM
Collegium to Present at Upcoming Investor Conferences GlobeNewswire Inc. - 4/1/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/19/2019 5:42:49 PM
Apophis   Monday, 12/11/17 01:52:08 PM
Re: None
Post # of 25 
Depomed farms out Nucynta sales, will lay off 40% of company
BY MarketWatch
— 5:03 PM ET 12/04/2017
DepoMed Inc.
) announced Monday afternoon that it will allow Collegium Pharmaceutical Inc. ( COLL ) to handle sales of its most lucrative product, the Nucynta line of painkillers, and slash its workforce. DepoMed
) said that it would take royalties as Collegium markets and sells Nucynta, and eliminate its painkiller salesforce and any brand advertising for the product. The company plans to lay off 40% of its workforce, about 70 employees, and move its headquarters out of Newark, California, to a state on the East Coast or in the Midwest. "Taking these steps, in terms of headcount reductions and office relocation, will provide additional financial and strategic benefits," DepoMed
) Chief Executive Arthur Higgins,who took the reins of the company earlier this year after an activist-investor battle (http:// www.marketwatch.com/story/depomed-dives-as-activist-investor-fight-leads-to-new-ceo-board-members-2017-03-28), said in a prepared statement. DepoMed
) will receive a minimum royalty of $135 million a year while cutting $70 million in annual expenses, the company said. Through nine months of this year, DepoMed
) has reported $183.3 million in Nucynta sales, more than half of its $286.3 million in total revenue. DepoMed
) and Collegium shares were both halted for a little more than a half-hour in late trading ahead of the announcement; after trading resumed, DepoMed ( DEPO ) shares, which were down more than 60% on the year, gained nearly 5% and Collegium shares added about 0.4%.


Any posts are just an opinion and should not be taken as investment advice. Always do your own DD
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist